ocrelizumab

ocrelizumab is a humanized anti-CD20 monoclonal antibody used in the treatment of multiple sclerosis and is marketed under the brand name Ocrevus. It is administered via intravenous infusion and represents a significant advancement in the management of both relapsing and progressive forms of the disease. Developed by the biotechnology company Genentech, a member of the Roche group, it was the first therapy approved by the U.S. Food and Drug Administration for primary progressive multiple sclerosis.

Medical uses

Ocrelizumab is indicated for the treatment of adult patients with relapsing-remitting multiple sclerosis and primary progressive multiple sclerosis. Clinical trials, including the pivotal OPERA I and OPERA II studies for relapsing disease and the ORATORIO trial for progressive disease, demonstrated its efficacy in reducing clinical relapses, disability progression, and MRI-detected brain lesions. Its use is typically overseen by specialists in neurology within settings equipped to manage infusion-related reactions. Treatment involves an initial dose followed by subsequent infusions every six months, as established in its prescribing information reviewed by regulatory bodies like the European Medicines Agency.

Adverse effects

The most common adverse reactions associated with ocrelizumab are infusion-related reactions, which can include symptoms such as pruritus, rash, dyspnea, and hypotension. These events are most frequent with the first infusion and often diminish with subsequent doses. Serious risks include an increased susceptibility to infections, notably upper respiratory tract infections and potential reactivation of latent viruses such as hepatitis B. Other important safety concerns involve a potential risk of malignancies, which was noted during clinical development, and rare but severe events like progressive multifocal leukoencephalopathy as has been observed with other anti-CD20 therapies. Monitoring protocols are recommended by health authorities including the Food and Drug Administration.

Pharmacology

As a monoclonal antibody, ocrelizumab selectively targets the CD20 antigen, a cell surface protein expressed on B lymphocytes but not on plasma cells or stem cells. This binding leads to antibody-dependent cellular cytotoxicity and complement-dependent cytotoxicity, resulting in the depletion of a broad range of CD20-positive B cells. The pharmacokinetics are characterized by a long elimination half-life, supporting its dosing schedule. Its mechanism of action is distinct from earlier multiple sclerosis treatments like interferon beta-1a or glatiramer acetate, focusing on the humoral immune component implicated in the pathophysiology of the disease.

History

The development of ocrelizumab originated from research into B cell involvement in autoimmune diseases conducted at Genentech. Following extensive clinical investigation, it received its first global approval from the U.S. Food and Drug Administration in March 2017 for both forms of multiple sclerosis. Subsequent approvals were granted by the European Commission and other regulatory agencies worldwide. The drug's development and approval history were significantly influenced by data presented to committees like the FDA's Psychopharmacologic Drugs Advisory Committee and involved collaborations with organizations such as the National Multiple Sclerosis Society.

Society and culture

Marketed under the brand name Ocrevus, ocrelizumab has had a substantial impact on the treatment landscape for multiple sclerosis, often discussed in medical forums like the American Academy of Neurology annual meeting. Its high cost has been a subject of debate within healthcare systems, involving discussions with payers like the National Health Service in the United Kingdom. Patient access programs have been established by Roche in various regions. The therapy has been featured in prominent medical journals such as The New England Journal of Medicine and has influenced treatment guidelines issued by bodies like the American Neurological Association.

Category:Monoclonal antibodies Category:Multiple sclerosis medications Category:Genentech